TAP PARTNER NEWS DURING ASCO: JUNE 2023
TAP PARTNER NEWS DURING ASCO: JUNE 2023
Gilead and Kite Oncology to Showcase Axicabtagene Ciloleucel Advances at ASCO 2023
May 17, 2023 - FOSTER CITY, Calif. & SANTA MONICA, Calif. - Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present several key abstracts during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, including a late-breaking presentation from the landmark Phase 3 ZUMA-7 study to detail overall survival results for axicabtagene ciloleucel showing statistical improvement over standard of care for initial treatment of relapsed/refractory large B-cell lymphoma.
MorphoSys Highlights Potential of Its Oncology Pipeline at 2023 ASCO Annual Meeting
Planegg/Munich, Germany, May 11, 2023 - MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced that the latest data on multiple pipeline therapies will be presented during the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois from June 2 to 6, 2023. A poster discussion presentation will include data on pelabresib, an investigational BET inhibitor.
Jazz Pharmaceuticals to Showcase Rapidly Expanding Oncology Pipeline and Advances in Current Product Portfolio at ASCO 2023
DUBLIN, April 27, 2023 - Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting from June 2-6, 2023. Presentations include clinical data from trials of Vyxeos® (daunorubicin and cytarabine).
NexImmune Announces Presentation of Phase 1/2 Clinical Data at the 2023 American Society of Clinical Oncology Annual Meeting
GAITHERSBURG, Md., April 26, 2023 - NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells for liquid and solid malignancies, today announced that clinical data from its Phase 1/2 dose escalation study of NEXI-001 will be presented in a poster session at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting in Chicago, June 2 – June 6, 2023.